Search for Clinical Trial Results

Sponsored By

Primary Central Nervous System Lymphoma - 27 Studies Found

Status Study
Not yet recruiting Study Name: Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2016-11-29
Interventions:
  • Dietary Supplement: ketogenic diet

Recruiting Study Name: MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2015-03-01
Interventions: Drug: R-MT followed by auto-HSCT Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3
Recruiting Study Name: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Condition: Primary Central Nervous System Lymphoma
Date: 2016-05-17
Interventions: Drug: pembrolizumab Pembrolizumab 200 mg every 3 weeks
Withdrawn Study Name: Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 1999-11-01
Interventions:
  • Drug: antineoplaston A10
  • Drug: antineoplas
Withdrawn Study Name: a Phase II Study in Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2007-04-02
Interventions:
  • Drug: Methotrexate
  • Drug: Methylprednisolon
Recruiting Study Name: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2016-01-07
Interventions: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing
Not yet recruiting Study Name: PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2017-04-10
Interventions: Drug: PQR309 Oral PQR309, 80mg or 60mg daily or intermittent dosing
Withdrawn Study Name: Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2008-07-03
Interventions: Drug: Pemetrexed 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until pr
Completed Study Name: Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Condition: Primary Central Nervous System Lymphoma
Date: 2005-09-13
Interventions:
  • Drug: Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C

Recruiting Study Name: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Condition: Primary CNS Lymphoma
Date: 2016-10-13
Interventions:
  • Drug: methotrexate
  • Drug: temozolomide
Next >>>